Family · Pharmaceutical analytical standards

Etelcalcetide

A calcimimetic approved in Europe in 2016 for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. It is the first of its class given intravenously: three times a week, at the end of the dialysis session. This family brings together the active ingredient.

Did you know?It is an unusual peptide: seven amino acids all in the D form, the mirror image of those that build our proteins, with a D-cysteine linked by a disulfide bridge to an L-cysteine.